United Therapeutics Corporation (UTHR) Receives Hold Rating from Cowen and Company

Cowen and Company reaffirmed their hold rating on shares of United Therapeutics Corporation (NASDAQ:UTHR) in a research note issued to investors on Friday morning. They currently have a $129.00 price target on the biotechnology company’s stock.

Several other research analysts have also recently issued reports on UTHR. HC Wainwright reissued a hold rating and issued a $95.00 price target on shares of United Therapeutics Corporation in a research note on Thursday, October 26th. TheStreet cut United Therapeutics Corporation from a b- rating to a c rating in a research note on Friday, September 29th. Jefferies Group LLC reissued a sell rating and issued a $105.00 price target on shares of United Therapeutics Corporation in a research note on Friday, July 14th. ValuEngine raised United Therapeutics Corporation from a hold rating to a buy rating in a research note on Monday, October 2nd. Finally, BidaskClub cut United Therapeutics Corporation from a hold rating to a sell rating in a research note on Monday, July 31st. Five investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of Hold and an average target price of $132.82.

Shares of United Therapeutics Corporation (NASDAQ:UTHR) opened at 119.86 on Friday. The stock has a market capitalization of $5.21 billion, a price-to-earnings ratio of 13.90 and a beta of 1.50. The firm’s 50 day moving average is $120.31 and its 200 day moving average is $125.68. United Therapeutics Corporation has a 12 month low of $112.01 and a 12 month high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $4.01 by $2.26. United Therapeutics Corporation had a return on equity of 26.24% and a net margin of 30.50%. The company had revenue of $445.50 million during the quarter, compared to analysts’ expectations of $426.43 million. During the same quarter in the prior year, the business posted $4.23 earnings per share. The company’s revenue for the quarter was up 9.1% compared to the same quarter last year. On average, equities analysts predict that United Therapeutics Corporation will post $10.60 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “United Therapeutics Corporation (UTHR) Receives Hold Rating from Cowen and Company” was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.com-unik.info/2017/10/31/united-therapeutics-corporation-uthr-receives-hold-rating-from-cowen-and-company.html.

In other news, CEO Martine A. Rothblatt sold 1,274 shares of the company’s stock in a transaction on Thursday, September 21st. The stock was sold at an average price of $116.07, for a total transaction of $147,873.18. Following the completion of the sale, the chief executive officer now directly owns 2,343 shares of the company’s stock, valued at $271,952.01. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 2,176 shares of the company’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $127.11, for a total value of $276,591.36. Following the sale, the chief executive officer now directly owns 3,245 shares of the company’s stock, valued at $412,471.95. The disclosure for this sale can be found here. Insiders have sold 18,368 shares of company stock valued at $2,295,419 in the last ninety days. Company insiders own 7.80% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in UTHR. Eagle Global Advisors LLC purchased a new stake in shares of United Therapeutics Corporation during the second quarter valued at $206,000. TLP Group LLC purchased a new stake in shares of United Therapeutics Corporation during the second quarter valued at $246,000. HPM Partners LLC lifted its holdings in shares of United Therapeutics Corporation by 0.8% during the second quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock valued at $257,000 after purchasing an additional 15 shares during the last quarter. Fort L.P. lifted its holdings in shares of United Therapeutics Corporation by 5.2% during the second quarter. Fort L.P. now owns 2,014 shares of the biotechnology company’s stock valued at $261,000 after purchasing an additional 99 shares during the last quarter. Finally, Prospera Financial Services Inc purchased a new stake in shares of United Therapeutics Corporation during the second quarter valued at $277,000.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Analyst Recommendations for United Therapeutics Corporation (NASDAQ:UTHR)

What are top analysts saying about United Therapeutics Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for United Therapeutics Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit